Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...